IDOV-Immune (oncolytic vaccinia virus)

Phase 1Biologic

IDOV-Immune (oncolytic vaccinia virus) is one of 50 biologic programs targeting Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerRecruiting

Colorectal CancerPhase 1

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 3

Adrucil

EElorac, Inc.

Phase 3

87 4

Acetylsalicylic Acid

Bayer

Phase 3

7 5

Trifluridine/tipiracil

AbbVie

Phase 3

3 6

Telisotuzumab Adizutecan

AbbVie

Phase 3

2 7

XL092

Roche

Phase 3

1 8

TAS 102

Taiho Oncology, Inc.

Phase 3

8 9

5-Fu

TToray Industries, Inc

Phase 3

3 10

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Colorectal Cancer

NCT06910657

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

Recruiting·VViroMissile, Inc.·Phase 1·NCT06910657·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IDOV-Immune (oncolytic vaccinia virus). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDOV-Immune (oncolytic vaccinia virus) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDOV-Immune (oncolytic vaccinia virus). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ViroMissile, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: VViroMissile, Inc.

IDOV-Immune (oncolytic vaccinia virus)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News